AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05347589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: post isometric relaxation of the Quadratus lumborum
Description: Post Isometric Relaxation: The patient will be in a left recumbent position with his leg in a fully flexed position close to his chest and fixed by his left hand. The patient is asked to hold the treatment table with a right hand in an overhead position to support the body in applying the technique. The patient fully extended left will be taken away from the treatment table. At this point, the patient will be asked to press the leg down until the range where the patient feels discomfort to the point of torsion of Quadratus lumborum. This is the point that is the barrier range. Smaller than this range the patient will be asked to lift his left against the counterforce by the therapist and hold it for five to seven seconds which will be followed by five to seven seconds of relaxation. The technique will be repeated by five times in the pain-free range
Study NCT05009472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: expander with deferential opening and petit face mask
Description: bonded expander with two screws and vertical hooks for attachment face mask. adjustment face mask with forehead and chin anchorage
Study NCT04991597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Lidocaine with epinephrine will be buffered 3:1 with sodium bicarbonate
Study NCT04991597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Lidocaine with epinephrine will be buffered 9:1 with sodium bicarbonate
Study NCT05497557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Sotorasib will be administered as an oral tablet.
Study NCT04971512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-721
Description: Oral administration (Part 1)
Study NCT04971512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 1)
Description: Placebo to match EDP-721, oral administration (Part 1)
Study NCT04971512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-721 (Part 2)
Description: Oral administration (Part 2)
Study NCT04971512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2)
Description: Placebo to match EDP-721 (Part 2)
Study NCT04971512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP-514
Description: Oral administration
Study NCT06569277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A mobile application
Description: Those who agreed to download a mobile app for colonoscopic bowel preparation on their smartphones.
Study NCT05639439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation using the Fastrach intubating laryngeal mask airway and glottic view using fibrescope - Group A
Description: Insertion of the intubating laryngeal airway device Fastrach, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)
Study NCT05639439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation using the Proseal laryngeal mask airway and glottic view using fibrescope- Group B
Description: Insertion of the laryngeal airway device Proseal, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)
Study NCT05639439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation using the I-gel supraglottic airway device and glottic view using fibrescope- Group C
Description: Insertion of the supraglottic airway device I-gel, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)
Study NCT04971512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part 2)
Description: Placebo to match EDP-514
Study NCT05639439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation using the Protector laryngeal airway device and glottic view using fibrescope- Group D
Description: Insertion of the laryngeal airway device Protector, evaluation of the ventilation sufficiency and perfection of installation/ anatomical application to the larynx (evaluation with fiberoptic bronchoscope)
Study NCT05472740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS 7000
Description: TENS device to be used in both the active and placebo groups
Study NCT05472740 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TENS 7000
Description: TENS device to be used in both the active and placebo groups
Study NCT04411654 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: LY3884961
Description: Participants will receive a single dose of LY3884961 administered intracisternally.
Study NCT04411654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Single IV pulse administered as concomitant medication.
Study NCT06164600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bovine colostrum
Description: A powdered form of the first 6 hours bovine colostrum \[65 mg lactoferrin, lactoperoxidase: 2.8 unit and immunoglobulins in the form of 350 mg IgG, 35.3 mg of Ig A and 25.3 mg Ig M\]
Study NCT06164600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo sachets will be provided by ImmuGuard® manufacturing company.
Study NCT06309433 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: dual energy x-ray absorptiometry
Description: Patient will undergo periodic (6-12-24m) dexa scans on the periprosthetic bone
Study NCT05444088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: intravenous infusion
Study NCT05444088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: intravenous infusion
Study NCT05444088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: intravenous infusion
Study NCT06517511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor Oral Tablet [Xpovio]
Description: Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.
Study NCT06517511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP Protocol
Description: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Study NCT06034431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ride Share
Description: The Investigators' proposed study addresses the Prostate Cancer Research Program overarching challenge of Advancing Health Equity and Reducing Disparities in PCa by examining and addressing travel burden to PCa treatment centers. Investigators will focus on Black men (including those of Caribbean descent), a high-risk population experiencing poorer health outcomes for unjust and preventable reasons.~This research will inform efforts to reduce travel burden in the healthcare acquisition process and improve the timeliness of treatment in Black men with PCa in Massachusetts and other states. This project will improve the quality of life and enhance outcomes and overall health and wellness for this group. Investigators will use findings from this pilot study to obtain future funding for a multicenter randomized clinical trial that will estimate the effect of equity - oriented programs that remove transportation barriers to treatment and reduce Black-White disparities in PCa outcomes
Study NCT05889741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: 6.5cc of Ropivacaine hydrochloride (HCl) 0.5%, one time into the stellate ganglion
Study NCT05889741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 6.5cc of Normal Saline one time into the stellate ganglion.
Study NCT05206045 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care for patients with Sezary Syndrome
Study NCT06222957 — intervention group
Intervention type: OTHER
Intervention: None (Observational study)
Description: Both groups recieve standard care as decided by the responsible clinicians at the department of Oncology. The course of the treatment is completely independent from the observations in the present study.
Study NCT04949087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glenohumeral Injection
Description: Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
Study NCT04949087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glenohumeral Injection
Description: Patients who enroll will be randomized into an injection group, and then will undergo the specified injection at one time point only.
Study NCT04535362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: session will include 3 infusions in the same order: nicotine (1 mg per 70 kg body weight) delivered over 5 minutes, saline and nicotine (1 mg/ 70 kg) delivered over 2.5 minutes.
Study NCT04720170 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Revascularization
Description: Angiogram and IVUS with revascularization of the lateral plantar artery and pedal arch on target foot.
Study NCT04411654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Loading dose, followed by maintenance doses, followed by dose tapering; administered as concomitant medication.
Study NCT04411654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administered orally as concomitant medication, followed by dose tapering.
Study NCT06548295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified constraint induced movement therapy (mCIMT)
Description: Restraint the involved extremity by using a mitten. Repetitive task practice i.e filling a glass, drinking a glass of water, and eating with a spoon , stacking cones and stacking blocks, grasping and releasing of an object, reaching forward and sideways, lifting and dropping of an object from the one end of table to the other end.~The shaping exercises included cube stacking, card turning, throwing balls into a box, grasping/holding and placing objects of different sizes, and drawing and painting exercises. Intervention: 5 sessions per week for 50 minutes for 6 weeks
Study NCT06548295 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: conservative treatment
Description: The conservative rehabilitation program consisted of upper-limb range of motion exercises, positioning, stretching, and strengthening exercises, Passive mobilization of the shoulder ,elbow , wrist and small joints of hand Stretching of the affected arm including biceps, triceps and muscles of forearm and hand.~Strengthening exercises of upper arm and forearm muscles involved. Intervention: 5 sessions per week for six weeks and 50 mintues
Study NCT06497829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: geranylgeraniol
Description: GG Pure (Extendlife Natural Products) containing GG gold®30 Annatto Extract, 500 mg capsule, use for 3 months, once daily
Study NCT06498986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06498986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib Mesylate Tablets
Description: Oral administration, 80mg daily for a cycle of 3 weeks.
Study NCT04682327 — intervention group
Intervention type: OTHER
Intervention: Response to anti-PD-1/PD-L1
Description: Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
Study NCT04682327 — intervention group
Intervention type: OTHER
Intervention: Non-response to anti-PD-1/PD-L1
Description: Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
Study NCT06049680 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SMOFlipid® (lipid injectable emulsion)
Description: SMOFlipid is a sterile, nonpyrogenic, white, homogenous lipid emulsion for intravenous infusion. The lipid content of SMOFlipid is 0.20 g/mL, and comprises a mixture of soybean oil, MCT, olive oil, and fish oil. SMOFlipid belongs to the pharmacotherapeutic group: Solutions for parenteral nutrition, fat emulsions (ATC-code: B05BA02). SMOFlipid is indicated in adult and pediatric patients, including term and preterm neonates, as a source of calories and essential fatty acids for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
Study NCT06256627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human interference'- α- 1b, interleukin-2, thalidomide, Venentoclax and Azacitidine
Description: Patients in arm1 were randomly divided into two groups, namely the  interference'- α- 1b, interleukin-2, thalidomide treatment group and the VA treatment group. After receiving a two cycle protocol, patients were evaluated for the endpoint of the trial and their MRD conversion rate was calculated.~Patients in arm2 will receive triple maintenance treatment, completing three alternative regimens into one cycle. The regimen maintenance treatment will be maintained for a total of 8 cycles. Each medication regimen takes 28 days as a cycle. The number of days administered per cycle can be adjusted based on the patient's blood count.
Study NCT06071884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bridge Percutaneous Nerve Field Stimulator
Description: The Bridge device is an FDA-cleared, drug-free, non-surgical device that uses neuro-modulation to aid in the reduction of symptoms associated with opioid withdrawal through application to branches of the Cranial Nerves V, VII, IX, X, and the occipital nerves. This study is investigating its effectiveness treating post-surgical pain.
Study NCT04449068 — intervention group
Intervention type: OTHER
Intervention: Neurological and neuropsychological Follow-up after deep brain stimulation
Description: Investigation of tic severity, psychiatric co-morbidities, quality of life, and neuropsychologcial measures until the 5-year after deep brain stimulation (DBS)
Study NCT05688267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous Mobility Training
Description: The continuous mobility training adopted 5 grading exercise level, which was evaluated and implemented by physical therapists, and focused on continuous mobility training courses with different levels. At each stage, the participants were instructed to perform spontaneous breathing exercise, which were confirmed by the physical therapists.
Study NCT05688267 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants of control group formed the routine care group, received the routine mechanical ventilation weaning plan and underwent hand bicycle training.
Study NCT05619887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl, when administered into the intrathecal (spinal) space suppresses feedback from the muscles below the site of action, i.e., the legs. It does not affect resting cardiorespiratory responses. We are using this to test what role the muscle reflex plays during exercise.
Study NCT05619887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An equal volume (as above) of saline will be administered into the intrathecal (spinal) space. This has no effect of cardiorespiratory responses at rest or during exercise; it is to control for the invasiveness of the procedure required to suppress muscle feedback in the experimental condition.
Study NCT06304844 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transient elastography (Fibroscan)
Description: conduct fibroscan for patients with (MAFLD by abdominal ultrasonography)
Study NCT05262595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0471-0119 A
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study NCT05092464 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural Lactic Acid-enriched Cream
Description: The subjects were required to topically apply natural lactic acid-enriched cream twice daily in the morning and evening for the treatment duration of 12 weeks.
Study NCT05001698 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: intravenous infusion (IV)
Study NCT05634941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active ON-tDCS
Description: DC was transmitted via a saline-soaked pair of surface sponges and delivered by specially developed, battery-driven, constant current stimulator with a maximum output of 2 mA. For each participant receiving ON-tDCS, the anodal electrode placed over the left C2 nerve dermatome, and cathodal electrode placed over the right C2 dermatome. A constant current of 1.5 mA was applied for 20 min.
Study NCT05634941 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham ON-tDCS
Description: For sham group, placement of the electrodes was identical to that of active ON-tDCS. ON-tDCS was first switched on in a ramp-up fashion over 5 s. Current intensity (ramp down) was gradually reduced (over 5 s) as soon as ON-tDCS reached a current flow of 1.5 mA. Hence, sham ON-tDCS only lasted 10 s (as opposed to 20 min in the active group).
Study NCT05569109 — intervention group
Intervention type: DEVICE
Intervention: doppler ultrasound
Description: doppler ultrasound on arteriovenous fistula in hemodialysis patients
Study NCT06564831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLAM + SOC
Description: Weekly Treatment visits for 12 weeks begin at day 0. SLAM applications with SOC until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT06564831 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Beginning at the screening visit, participants will receive weekly treatment with standard of care (cleaning, debridement, ulcer moisture balance, and offloading) until ulcer closure, or a maximum of 12 weeks, whichever occurs first.
Study NCT05051098 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06140667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LarysealTM Pro
Description: The LarysealTM Pro is the new generation mask for safe and effective airway management, as it could reduce the risk of aspiration by the integrated suction catheter port to allow effective removal of fluids and gastric contents. So that, it could be a promising airway device as its symmetrical cuff and tube contoured to match the oropharyngeal anatomy for quick and easy first time insertion success. It could be applied in both routine and advanced airway management for patients with a higher risk of a difficult airway, unexpected intubation difficulties, beside to airway control during anesthesia. It was presented in the clinical market in sizes 3, 4 and 5 (according to the body weight; size 3: 30-50Kg, size 4: 50-70 Kg, and size 5:70-100Kg) that can accept larger tracheal tube up to 7.5 and 8mm inner diameter respectively with maximum suction catheter size of 16 Fr.
Study NCT06140667 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ambu Aura Gain
Description: The AuraGain is Ambu ꞌs 3rd generation disposable laryngeal mask, satisfying 3 fundamental airway management needs by integrating gastric access channel for managing gastric content and intubation capability using standard ET-tubes in an anatomically curved single-use device that facilitates rapid establishment of a safe airway through integrated bite absorption area that could prevent airway occlusion. Other characters include pilot balloon that identifies mask size and provides tactile indication of degree of inflation, navigation marks for guiding flexible scope and is made of phthalate-free material. Its thin and soft cuff is designed to deliver high seal pressure up to 40 cmH2O. It was presented in the clinical market in sizes 3, 4, 5 and 6 (according to the body weight; size 3: 30-50 kg, size 4: 50-70 kg, size 5: 70-100 kg, and size 6: >100 kg) with maximum suction catheter size of 16 Fr.
Study NCT05594563 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFMO
Description: DFMO orally twice a day
Study NCT05594563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo orally twice a day
Study NCT05204784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rheopheresis treatment
Description: After obtaining venous access, anticoagulated blood is pumped through a plasmafilter. The plasma is then run through the Rheofilter and large plasma proteins are removed. Finally, cells are reinfused, and blood is returned to the patient.
Study NCT05204784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Infusion
Description: Standard of care treatment consists of intravenous iloprost infusions at a dose of 0.5-2 ng/kg/min administered over at least 6 hours as per local standard
Study NCT05515679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BRAIN App
Description: The BRAIN App will be the first-ever artificial intelligence enabled cognitive stimulation therapy app, specifically designed for PWD. The goal of the app is to foster positive relationships between the care triad.
Study NCT06146738 — intervention group
Intervention type: BEHAVIORAL
Intervention: Palliative Care
Description: Best supportive care without surgical intervention
Study NCT06146738 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor biopsy
Description: Tumor biopsy
Study NCT06146738 — intervention group
Intervention type: PROCEDURE
Intervention: Tumor resection
Description: Maximal safe resection of the tumor
Study NCT04802863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XNW4107, Imipenem/Cilastatin
Description: Five doses of 250 mg XNW4107 in combination with 500 mg imipenem/500 mg cilastatin